Proposed article structure
This article is organized into the following sections: clinical background and unmet need; study design and quality-improvement intervention; key results; clinical interpretation and implementation relevance; strengths and limitations; implications for practice and future research; funding and citation. This structure is designed to mirror how clinicians assess practice-changing implementation studies: first the problem, then the intervention, then the magnitude and credibility of effect.
Highlight
First, the study addresses a practical and common perioperative emergency problem: post-tonsillectomy hemorrhage (PTH), a complication that can be frightening for families and can rapidly escalate to airway compromise or substantial blood loss.
Second, the investigators did not simply test nebulized tranexamic acid (TXA) as a drug intervention; they evaluated whether a clinical care guideline (CCG), paired with an Emergency Department (ED) order set, could drive reliable uptake in real-world practice.
Third, after implementation, adherence appeared high. Among patients who met inclusion criteria for TXA, 81.3% received treatment, and order set utilization among those receiving TXA in the ED reached 95.7%.
Fourth, guideline implementation was associated with a substantial reduction in operative hemorrhage management, with returns to the operating room decreasing from 50.0% before implementation to 27.1% after implementation (p = 0.001; absolute risk reduction 0.320, 95% CI 0.116-0.500).
Background and clinical context
Post-tonsillectomy hemorrhage remains one of the most consequential complications after tonsillectomy. Although the overall incidence is relatively low, the event carries disproportionate clinical importance because it can present unpredictably, often outside routine clinic hours, and may require urgent ED evaluation, airway protection, resuscitation, or operative hemostasis. PTH also generates high anxiety for caregivers and frequently mobilizes multidisciplinary hospital resources, including emergency medicine, otolaryngology, anesthesia, and perioperative nursing teams.
Management of PTH is often heterogeneous. Some patients present with active oropharyngeal bleeding; others have a clot in the tonsillar fossa but are not actively bleeding at the time of evaluation. A subset will clearly require immediate operative intervention, particularly in the setting of brisk hemorrhage, hemodynamic instability, inability to manage secretions, or concern for airway compromise. Yet many cases fall into a gray zone in which clinicians aim to temporize bleeding, stabilize the patient, and potentially avoid the operating room if bleeding ceases and the patient remains clinically well.
Tranexamic acid is a synthetic antifibrinolytic that inhibits plasminogen activation and reduces clot breakdown. Systemic TXA has established roles in several bleeding settings, including trauma, postpartum hemorrhage, and selected perioperative contexts. Nebulized TXA has attracted growing attention as a localized, low-barrier strategy for upper airway or aerodigestive bleeding, including hemoptysis and epistaxis, and more recently PTH. The biologic rationale is straightforward: local deposition of an antifibrinolytic agent onto the bleeding mucosal surface may stabilize formed clot and reduce ongoing oozing without the procedural burden of intravenous access or immediate surgery.
However, even when an intervention is promising and mechanistically plausible, adoption in hospital care can be slow. Staff turnover, variable clinician familiarity, formulary access, inconsistent triage workflows, and the absence of standardized order pathways all contribute to underuse. This is especially true in emergency settings where time pressure is high and rare-but-high-stakes conditions must be managed reproducibly. The present study is therefore important not only because it examines nebulized TXA, but because it evaluates a practical implementation strategy to normalize its use.
Study design and intervention
Lavin and colleagues conducted a before-and-after quality-improvement study evaluating implementation of a clinical care guideline for nebulized TXA in PTH. The team used Model for Improvement methodology to design and operationalize the protocol, an appropriate framework when the objective is reliable uptake of a care process within a functioning health system rather than explanatory efficacy testing under tightly controlled conditions.
The intervention centered on a clinical algorithm for ED patients presenting with post-tonsillectomy bleeding. Patients with active bleeding or a visible blood clot were considered eligible to receive three nebulized TXA treatments. Exclusion criteria were clinically sensible and emphasized patient safety: severe bleeding, absence of active bleeding or clot, and inability to tolerate treatment or protect the airway. These exclusions implicitly recognize that nebulized TXA is a temporizing or nonoperative measure for selected patients, not a substitute for urgent airway management or surgical control in unstable presentations.
An order set was created to facilitate implementation, a critical step in translating protocol intent into bedside behavior. Standardized electronic order sets reduce cognitive load, improve consistency across clinicians, and support nursing and pharmacy workflows. The investigators compared data from two years before and two years after CCG initiation.
The reported measures included ED returns for PTH, TXA order set use, frequency of TXA administration, returns to the operating room, and secondary returns to the ED. This combination of process and outcome measures is a strength of the design. Process metrics determine whether the intervention was actually adopted; outcome metrics help assess whether that adoption was associated with clinically meaningful change.
Study population
There were 2805 tonsillectomies in the pre-implementation period and 5382 in the post-implementation period. The groups did not differ by patient age, which reduces concern that a major age shift explained the observed differences. The absolute number of surgeries was notably larger in the post-implementation interval, suggesting that the observed reduction in operative intervention occurred despite a larger procedural denominator and a larger number of PTH presentations overall.
ED returns for bleeding were 70 of 2805 tonsillectomies (2.5%) before implementation and 155 of 5382 (2.9%) after implementation, a difference that was not statistically significant (p > 0.05). This finding is useful because it suggests the guideline did not simply change thresholds for recognizing or documenting postoperative bleeding events. Rather, the overall burden of ED return for hemorrhage remained similar, while downstream management changed.
Key findings
Rapid protocol uptake
Among post-implementation patients, 126 met inclusion criteria for TXA, representing 81.3% of the PTH cohort. This indicates that the majority of ED PTH presentations were considered clinically suitable for the pathway, reinforcing the protocol’s practical applicability.
Order set utilization among patients receiving TXA in the ED was 95.7%, which is an impressive implementation result. In quality-improvement work, sustained change depends less on enthusiasm for an intervention and more on system design that makes the desired action easy and the undesired variation harder. This high rate strongly suggests the care pathway became embedded in workflow rather than remaining a niche practice used only by a few champions.
Association with reduced operative management
The most clinically important result was the reduction in operative PTH management. Before the intervention, 35 of 70 patients with ED return for PTH underwent operative control, a rate of 50.0%. After implementation, 42 of 155 required operative management, a rate of 27.1%.
This corresponds to a statistically significant difference (p = 0.001) and an absolute risk reduction of 0.320, with a 95% confidence interval of 0.116 to 0.500. In practical terms, the association suggests that standardizing nebulized TXA use in eligible patients was linked to meaningfully fewer returns to the operating room. For patients and hospitals alike, that is a highly relevant outcome. Avoiding operative intervention may reduce anesthesia exposure, perioperative risk, care fragmentation, resource utilization, and cost, while also potentially shortening the patient’s overall episode of care.
Interpretation of the effect size
The absolute reduction of 32 percentage points is substantial. Even allowing for the limitations of a nonrandomized before-and-after design, this magnitude is difficult to dismiss as trivial. At the bedside, the result suggests nebulized TXA may provide more than marginal symptom control; within a structured pathway, it may alter disposition and treatment intensity for selected patients with PTH.
At the same time, the confidence interval is broad, ranging from 11.6 to 50.0 percentage points, which reflects some uncertainty around the exact size of effect. The direction of association is favorable, but the true benefit could be moderate rather than dramatic. Nonetheless, even the lower bound would remain clinically meaningful in this setting.
Clinical interpretation
This study is best understood as an implementation study with patient-centered clinical implications. It shows that a hospital can take an emerging therapy, define eligibility and exclusions, build an electronic order set, and achieve rapid, durable adherence. That alone is important. Many promising interventions fail not because they do not work, but because institutions never operationalize them effectively.
The clinical signal is equally compelling. PTH is a situation in which a safe, quickly deployable, locally acting therapy is attractive. Nebulized TXA does not require sedation, invasive access, or transport to the operating room. It can be administered while the otolaryngology team is evaluating the patient, while the patient is fasting in case surgery becomes necessary, and while monitoring proceeds. In this sense, it fits naturally into emergency workflows as a temporizing and potentially definitive measure in selected cases.
Importantly, the exclusion of severe bleeding and patients unable to tolerate treatment or protect the airway reinforces an essential principle: nebulized TXA should not delay definitive management in unstable patients. The intervention is most relevant for the large intermediate-risk group with active bleeding or clot but without immediate indications for operative control.
Strengths of the study
The study has several practical strengths. First, it addresses a real-world care gap rather than a purely theoretical question. Second, the quality-improvement framework is appropriate for the implementation problem being tackled. Third, the investigators measured both process reliability and patient-centered outcomes. Fourth, the use of explicit inclusion and exclusion criteria improves reproducibility and makes the pathway easier for other centers to adapt.
The large tonsillectomy denominators across pre- and post-periods also provide useful institutional context. In addition, the lack of a significant difference in ED bleeding returns argues against the possibility that the post-intervention cohort merely represented a lower-risk bleeding population overall.
Limitations and caution in interpretation
As with all before-and-after studies, causality cannot be definitively established. Secular changes in surgical technique, postoperative counseling, thresholds for admission, ED practice patterns, otolaryngology consultation habits, or operating room decision-making could have contributed to the observed reduction in operative management.
The abstract does not report detailed safety outcomes, such as bronchospasm, intolerance, aspiration concerns, or delayed bleeding events attributable to temporary clot stabilization without durable hemostasis. While nebulized TXA is generally considered low risk, especially in localized use, formal safety reporting remains important when protocols are scaled.
The study also does not provide granular data on bleeding severity, timing of hemorrhage relative to surgery, admission rates, transfusion requirements, or whether patients avoided surgery only initially but later required intervention after discharge. Secondary ED returns were listed among measures, but detailed rates are not included in the abstract. Those data would be valuable in determining whether reduced immediate operative management translated into durable control rather than deferred recurrence.
Another limitation is generalizability. Institutions with different ED staffing, pharmacy processes, ENT coverage models, or patient age distributions may not reproduce the same degree of adoption or outcome benefit. Yet the very high order set use suggests that the implementation principles themselves are likely transferable, even if exact effect sizes differ.
Implications for clinical practice
For centers that manage a meaningful volume of tonsillectomy patients, this study provides a strong operational argument for standardizing PTH management. A well-designed CCG can reduce variability, clarify when nebulized TXA is appropriate, and preserve escalation pathways for patients with unstable bleeding or airway risk.
Clinicians considering adoption should focus on several components: clearly defined eligibility criteria; explicit exclusion criteria emphasizing airway safety and severe hemorrhage; electronic order set integration; nursing and respiratory therapy education; and coordination between emergency medicine, otolaryngology, anesthesia, and pharmacy. A protocol is most likely to succeed when it is embedded in the system rather than dependent on individual memory.
For clinicians at the bedside, the main takeaway is not that nebulized TXA replaces operative management. Rather, it appears to be a valuable adjunct and, in selected patients, a potentially surgery-sparing therapy when delivered within a structured pathway. This nuance matters. The study supports protocolized use, not indiscriminate use.
Future research directions
The next scientific step is stronger comparative effectiveness evidence. Multicenter prospective studies, ideally with standardized severity assessment and safety reporting, would help define which PTH phenotypes benefit most. Randomized trials may be challenging in emergency settings but would be valuable if feasible. At minimum, multicenter prospective registries could compare nebulized TXA protocols, dosing strategies, need for repeat administration, recurrence rates, admission outcomes, and patient-reported experience.
Economic evaluation would also be useful. If nebulized TXA meaningfully reduces operating room use, the intervention may have favorable cost implications even after accounting for implementation effort. Finally, future studies should examine balancing measures such as delayed hemorrhage, transfer rates, aspiration events, and any instances in which TXA use might have postponed needed definitive management.
Conclusion
Lavin and colleagues provide important evidence that implementation matters. In this hospital-based quality-improvement study, a clinical care guideline and ED order set enabled rapid uptake of nebulized TXA for eligible post-tonsillectomy hemorrhage presentations. That implementation was associated with a marked reduction in operative management, from 50.0% to 27.1%, with a statistically significant absolute risk reduction of 0.320.
For clinicians, the message is practical: nebulized TXA appears to be a useful nonoperative tool for selected PTH patients, and standardized pathways may be the key to realizing its benefit consistently. For health systems, the study is a reminder that translating promising therapies into routine care requires deliberate workflow design. For researchers, it sets the stage for prospective studies that better define safety, durability, and the patients most likely to avoid surgery.
Funding and ClinicalTrials.gov
Funding information was not provided in the source abstract. No ClinicalTrials.gov registration number was reported, which is consistent with the quality-improvement and implementation nature of the project rather than a registered interventional trial.
Citation
Lavin J, Billings K, Smith A, Patel K, Corboy J, Hazkani I. Clinical Care Guideline Implementation of Nebulized Tranexamic Acid in Post-Tonsillectomy Hemorrhage. Laryngoscope. 2026 May 29. doi: 10.1002/lary.70641. Epub ahead of print. PMID: 42212485.
